PT-141
PT-141 (Bremelanotide) • Also called PT 141, Bremelanotide
PT-141 benefits from an FDA-approved reference product, making it one of the more defensible peptides from a compliance standpoint.
Current status
Legal
Sexual-wellness interest, with current federal compounding constraints still in play.
FDA category
FDA Approved
Can pharmacies compound this?
Yes
Reclassification expected?
Unclear
The approved-drug pathway gives PT-141 much stronger footing than most peptides tracked here.
Primary Use
Sexual-wellness interest
Also searched as
PT 141, Bremelanotide
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Jul 1, 2025
Ingredient remained available through approved or established compounding pathways.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when PT-141 status changes
State-specific notes
Tennessee
Remains a common compliant option for wellness clinics.